Yshai Yavin

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

Vlado Perkovic, Meg Jardine, Bruce Neal et al. · New England Journal of Medicine · 2019 · 6K citations · Full text

Medicine, Nephrology, Pharmacology +17

Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups

Kenneth W. Mahaffey, Meg Jardine, Séverine Bompoint et al. · Circulation · 2019 · 288 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +17

Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial

Taha Sen, Jingwei Li, Brendon L. Neuen et al. · Diabetologia · 2021 · 83 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial

Ashish Sarraju, Jingwei Li, Christopher P. Cannon et al. · American Heart Journal · 2020 · 81 citations · Full text

Medicine, Cardiology, Internal Medicine +14

Effect of the SGLT2 Inhibitor Dapagliflozin on Potassium Levels in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis

Yshai Yavin, Traci A. Mansfield, Agata Ptaszynska et al. · Diabetes Therapy · 2016 · 59 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17